Pentaomix is developing a novel modality for digital pathology that aims to revolutionize the ability of doctors to match each cancer patient with the right drug. The companys system is based on hyperspectral imaging and AI algorithms to enable a deeper understanding of the tumors microenvironment and a holistic viewpoint of the tumor progression. The Pentaomix system will enable a shorter development time for cancer drug biomarkers and improved screening for clinical studies, and will eventually serve as a companion diagnostic in hospitals.